22 active not recruiting. 22 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Active not recruiting 22 |
| Phase 2 | 5 | Active not recruiting 5 |
Follow Neuroblastoma: new trials by email Literature Review of Neuroblastoma trials Research Report on Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma PHOX2B PC-CAR T Cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Active not recruiting | Stephan Grupp MD PhD | 38 | 2025-06-20 | 2026-07-01 |
| Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma GD2 CAR T cells - Neuroblastoma | Phase 1 | Active not recruiting | University College, London | 12 | 2024-04-19 | 2026-04-24 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-06-15 |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab Natural Killer Cells, Temozolomide, Irinotecan - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Active not recruiting | Nationwide Children's Hospital | 31 | 2022-09-01 | 2026-09-16 |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors VAL-413, Temozolomide - Solid Tumors, Neuroblastoma | Phase 1 | Active not recruiting | Valent Technologies, LLC | 20 | 2021-10-25 | 2026-07-30 |
| PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) - Neuroblastoma, Diffuse Intrinsic Pontine Glioma | Phase 1 | Active not recruiting | University of Florida | 24 | 2021-09-20 | 2026-09-23 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 68 | 2020-07-13 | 2026-04-28 |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma LY3295668 Erbumine, Topotecan, Cyclophosphamide - Neuroblastoma | Phase 1 | Active not recruiting | Eli Lilly and Company | 71 | 2020-06-11 | 2026-08-21 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 44 | 2019-06-18 | 2026-10-08 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas CLR 131 - Pediatric Solid Tumor, Pediatric Lymphoma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 30 | 2019-04-30 | 2026-10-01 |
| C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) C7R-GD2.CART cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 94 | 2019-04-23 | 2026-07-06 |
| Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Dinutuximab, NK Cells, Lenalidomide - Neuroblastoma | Phase 1 | Active not recruiting | New Approaches to Neuroblastoma Therapy Consortium | 13 | 2019-01-14 | 2026-03-23 |
| Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma Nivolumab, Ch14.18/CHO - Neuroblastoma | Phase 1 | Active not recruiting | University Hospital Southampton NHS Foundation Trust | 44 | 2018-05-24 | 2026-04-28 |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors GD2-CART01 - Neuroblastoma, Neuroblastoma Recurrent | Phase 1 / Phase 2 | Active not recruiting | Bambino Gesù Hospital and Research Institute | 42 | 2018-01-05 | 2026-09-30 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Entrectinib - Solid Tumors, CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 69 | 2016-05-03 | 2026-09-23 |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Sorafenib, Cyclophosphamide, Topotecan - Neuroblastoma | Phase 1 | Active not recruiting | New Approaches to Neuroblastoma Therapy Consortium | 18 | 2015-10-08 | 2026-03-23 |
| Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells) - Neuroblastoma, Ganglioneuroblastoma | Phase 1 | Active not recruiting | Seattle Children's Hospital | 65 | 2014-11-25 | 2026-05-19 |
| iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma GD2 T cells, VZV vaccine, Fludarabine - Osteosarcoma, Neuroblastoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 26 | 2014-04-01 | 2026-04-22 |
| 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan - Neuroblastoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 11 | 2013-08-01 | 2026-04-06 |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis - Recurrent Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 27 | 2013-02-04 | 2026-09-04 |
Showing 20 of 22. Sign in to see all of them.
Sarcoma, Ewing (7) · Osteosarcoma (6) · Sarcoma (6) · Rhabdomyosarcoma (5) · Recurrence (4) · Wilms Tumor (4) · Desmoplastic Small Round Cell Tumor (3) · Hepatoblastoma (3) · Medulloblastoma (3) · Rhabdoid Tumor (3) · Sarcoma, Synovial (3) · Brain Neoplasms (2) · Carcinoma (2) · Central Nervous System Neoplasms (2)
Neoplasms by Histologic Type (22) · Neoplasms, Glandular and Epithelial (22) · Neoplasms, Nerve Tissue (22) · Neuroectodermal Tumors (22) · Neuroectodermal Tumors, Primitive, Peripheral (22) · Neoplasms (21) · Neoplasms, Neuroepithelial (21) · Neuroectodermal Tumors, Primitive (21) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Bone Tissue (8) · Neoplasms, Connective Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms by Site (7) · Nervous System Diseases (7) · Nervous System Neoplasms (6)
Cyclophosphamide (5) · dinutuximab (3) · IL32 protein, human (2) · Lenalidomide (2) · Temozolomide (2) · Topotecan (2) · fludarabine (2) · fludarabine phosphate (2) · pembrolizumab (2) · Antibodies (1) · CLR1404 (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Herpes Zoster Vaccine (1) · Immunoglobulin G (1) · Irinotecan (1)
Baylor College of Medicine (4) · Seattle Children's Hospital (3) · Memorial Sloan Kettering Cancer Center (2) · New Approaches to Neuroblastoma Therapy Consortium (2) · Bambino Gesù Hospital and Research Institute (1) · Cellectar Biosciences, Inc. (1) · Eli Lilly and Company (1) · Hoffmann-La Roche (1) · National Cancer Institute (NCI) (1) · Nationwide Children's Hospital (1) · Stephan Grupp MD PhD (1) · University College, London (1) · University Hospital Southampton NHS Foundation Trust (1) · University of Florida (1) · Valent Technologies, LLC (1)
United States (20) · Canada (4) · United Kingdom (4) · Italy (3) · Australia (2) · France (2) · Germany (2) · Spain (2) · Belgium (1) · China (1) · Hong Kong (1) · Japan (1)
Catherine Albert, MD (2) · Aerang Kim, M.D. (1) · Alok Kothari, M.D. (1) · Araz Marachelian (1) · Araz Marachelian, MD, MS (1) · Bilal Omer, MD (1) · Brian Kushner, MD (1) · Cliona Rooney, PhD (1) · Duane Mitchell, M.D., Ph.D. (1) · Erin Trovillion, M.D. (1) · Giselle Sholler, MD (1) · Helen Heslop, MD (1) · Jacquelyn Crane, MD (1)
PMID 31401903, PMID 11118469, PMID 12091876, PMID 12218188, PMID 15269160, PMID 1576319, PMID 15869455, PMID 15950727, PMID 16382236, PMID 1638557, PMID 1643631, PMID 17369569, PMID 19047298, PMID 19171714, PMID 19304016, PMID 19626208, PMID 19638464, PMID 20570856, PMID 20879881, PMID 21074057, PMID 21149662, PMID 21298742, PMID 21798350, PMID 22186141, PMID 22658127, PMID 22658128, PMID 22700000, PMID 22844125, PMID 23649004, PMID 23661160, PMID 23724867, PMID 24333097, PMID 24848257, PMID 2514231, PMID 25604432, PMID 26320062, PMID 26785755, PMID 28183713, PMID 29147617, PMID 30326045, PMID 3094017, PMID 31838007, PMID 34772439, PMID 35395680, PMID 37018492, PMID 37018497, PMID 39255444, PMID 40086048, PMID 40841488, PMID 41299684
P01CA094237 (2), 2016 (1), 2019 (1), 2023 (1), P01CA081403 (1)